Subtype Report: Marginal Zone Lymphoma

Under the banner of MZL are EMZL, NMZL and SMZL despite the fact that their clinical and molecular characteristics are distinct from each other. A clearer understanding of the genomics of the subgroups of MZL as well as improved data regarding biological markers can help improve patient diagnosis and outcomes.

MZL has a distinct lack of large databases, clinical data and standard of care. There needs to be a more concentrated effort to increase clinical trials for MZL patients in order to analyse the efficacy of treatments. By working together and collaborating, national and international research groups have an opportunity to create a more tailored and relevant treatment protocol.

 Globally, patient access to care is often incomplete and sporadic. There are regional differences where access to novel and recommended therapies is not universal. With this information, the lymphoma community and LC members can work together to find solutions to gain broader access for patients. Having said that, the first step should be supporting research in developing a best practice for treatment of MZL. 


subtype report mzl

Click here to view or download the report.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.